Blood-forming stem cells found in bone marrow are the life-saving component used in bone marrow transplants. However, suitable donors often cannot be found in many cases. This study reveals how the human embryo develops the precursor to blood forming stem cells, which researchers say can be used in the novel method they developed to generate blood-forming stem cells from cells in tissue culture.
The study—led by researchers from Mount Sinai and the San Raffaele Telethon Institute for Gene Therapy in Milan Italy—confirms many aspects of cell development, including origins and regulation, which are known to occur within both the mouse and human embryo. In the mammalian embryo, blood-forming stem cells emerge from a specialized cell type called hemogenic endothelium. These cells develop in response to a critical signal pathway known as retinoic acid, which is essential for growth. Their analysis found that stem cell populations derived from human pluripotent stem cells were transcriptionally similar to cells in the early human embryo.
For years, researchers in the field of regenerative medicine have been able to obtain hemogenic endothelium from embryonic stem cells, but these cells do not produce blood-forming stem cells. In the embryo, blood-forming stem cell development requires signaling by retinoic acid. But, current state-of-the-art methods for deriving blood progenitors from human pluripotent stem cells do so in the absence of retinoic acid. In this latest study, researchers examined the dependence on retinoic acid in early cell types derived from human pluripotent stem cells. They performed single cell RNA sequencing of stem cells in vitro to better understand patterns of mesodermal cell types during early development. The research team identified a new strategy to obtain cells that are transcriptionally similar to those hemogenic endothelial cells found in the human embryo by stimulating a very discrete original population with retinoic acid.
scRNA-seq reveals distinct mesoderm populations
a,b, UMAP plots of sample origin (a) or transcriptionally distinct clusters (b) within WNTi or WNTd day 3 of differentiation cultures. c, Expression of KDR, GYPA or CDX genes within each differentiation culture. Colour bar: relative expression scaled for KDR and GYPA, and calculated module score for expression of CDX1/2/4. d, Clusters of WNTd KDR+ cells. UMAP plots visualizing (i) clustering of KDR+ WNTd cells, (ii) ALDH1A2 and (iii) CXCR4 expression. Colour bar: scaled expression within KDR+ mesodermal cells. e, Mesodermal CXCR4 expression under WNTd or WNTi differentiation conditions. (i) Representative flow cytometric analysis of KDR and CXCR4 expression on day 3 of differentiation, following control, WNTi or WNTd differentiation conditions. (ii) Quantification of CXCR4+ cells within each KDR+ fraction, on day 3 of differentiation, across various hPSC lines. Two-way analysis of variance (ANOVA) with Tukey’s test comparing all biological replicates: H1 (n = 12; control versus WNTi, P = 0.0112; control versus WNTd, WNTi versus WNTd, P < 0.0001), H9 (n = 5; control versus WNTi, P = 0.1388; control versus WNTd, P = 0.0008; WNTi versus WNTd, P < 0.0001) and iPSC-1 (control n = 5, WNTi/WNTd n = 7; control versus WNTi, P = 0.0003; control versus WNTd, P = 0.1109; WNTi versus WNTd, P < 0.0001). f, Expression of CYP26A1, ALDH1A1 and ALDH1A2 in day 3 KDR+ cells, as in e. SEM, two-way ANOVA with Tukey’s test comparing all biological replicates (n = 3), CD235a+ versus CXCR4+ (CYP26A1, P = 0.152225; ALDH1A1, P = 0.068067; ALDH1A2, P = 0.003529), CD235a+ versus CXCR4neg (CYP26A1, P = 0.140911; ALDH1A1, P = 0.103219; ALDH1A2, P = 0.010088), CXCR4+ versus CXCR4neg (CYP26A1, P = 0.000833; ALDH1A1, P = 0.429912; ALDH1A2, P = 0.035653). g, WNTd KDR+ cells with ALDEFLUOR (AF) activity have enriched expression of ALDH1A2. (i) Representative AF flow cytometric analysis. (ii) ALDH1A2 and CYP26A1 expression within CXCR4+/negALDF+/neg KDR+ cells. One-way ANOVA with Tukey’s test comparing all biological replicates (n = 3).
This new method brings researchers and scientists closer to developing blood-forming stem cells in tissue culture, but also provides a pathway to establishing specialized blood cell types for transfusions and other treatments for cancer since the new method makings it possible to obtain the same original cells in adult blood that are found in a developing embryo.
“We have made a major breakthrough in our ability to direct the development of stem cells in a tissue culture dish into cells that have the same gene expression signature as the immediate progenitor of a blood-forming stem cell found in the developing embryo. With this, now we can focus our efforts at understanding how to capture embryonic blood-forming stem cells, with the goal of using them as a substitute for bone marrow,” said Mount Sinai’s Dr. Christopher Sturgeon.
Source – Eurekalert